Novo-Nordisk A/S News

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

18:18

6-K: Financial Report for the Period 1 January 2024 to 31 March 2024

May 2 19:18

6-K: Novo Nordisk A/S - Share Repurchase Programme

May 1 21:09

6-K: Novo Nordisk A/S – Total Number of Voting Rights and Share Capital in Novo Nordisk A/S as of 26 April 2024

Apr 26 20:43

6-K: Articles of Association of Novo Nordisk A/S

Apr 25 18:10

6-K: Novo Nordisk A/S – Reduction of the Share Capital

Apr 25 18:05

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Apr 22 22:00

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Apr 17 18:10

Novo-Nordisk A/S | 6-K: Trading in Novo Nordisk Shares by Board Members, Executives and Associated Persons

Apr 17 18:10

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Apr 8 23:12

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Apr 2 20:04

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Apr 2 01:01

Novo-Nordisk A/S | 6-K: Articles of Association of Novo Nordisk A/S

Mar 25 22:48

Novo-Nordisk A/S | 6-K: Awiqli® (Once-Weekly Basal Insulin Icodec) Recommended for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Mar 22 18:11

Novo-Nordisk A/S | 6-K: Resolutions from the Annual General Meeting of Novo Nordisk A/S

Mar 22 00:16

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Mar 18 23:00

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Mar 12 01:17

Novo-Nordisk A/S | 6-K: Wegovy® Approved in the Us for Cardiovascular Risk Reduction in People with Overweight or Obesity and Established Cardiovascular Disease

Mar 9 03:56

Novo-Nordisk A/S | 6-K: Novo Nordisk Announced the Headline Results from the Kidney Outcomes Trial FlOW

Mar 5 21:32

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Mar 4 23:55